GB0614608D0 - Compounds having CRTH2 antagonist activity - Google Patents

Compounds having CRTH2 antagonist activity

Info

Publication number
GB0614608D0
GB0614608D0 GB0614608A GB0614608A GB0614608D0 GB 0614608 D0 GB0614608 D0 GB 0614608D0 GB 0614608 A GB0614608 A GB 0614608A GB 0614608 A GB0614608 A GB 0614608A GB 0614608 D0 GB0614608 D0 GB 0614608D0
Authority
GB
United Kingdom
Prior art keywords
compounds
antagonist activity
crth2 antagonist
crth2
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0614608A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxagen Ltd
Original Assignee
Oxagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxagen Ltd filed Critical Oxagen Ltd
Priority to GB0614608A priority Critical patent/GB0614608D0/en
Publication of GB0614608D0 publication Critical patent/GB0614608D0/en
Priority to CN2007800318258A priority patent/CN101506159B/en
Priority to KR1020097003615A priority patent/KR20090042808A/en
Priority to AU2007279079A priority patent/AU2007279079A1/en
Priority to RU2009101297/04A priority patent/RU2458918C2/en
Priority to CA002658496A priority patent/CA2658496A1/en
Priority to PL07766323T priority patent/PL2046740T3/en
Priority to MX2009000801A priority patent/MX2009000801A/en
Priority to DK07766323.5T priority patent/DK2046740T3/en
Priority to UAA200900835A priority patent/UA97957C2/en
Priority to PT07766323T priority patent/PT2046740E/en
Priority to EP07766323A priority patent/EP2046740B1/en
Priority to EP12168896A priority patent/EP2492268A1/en
Priority to ES07766323T priority patent/ES2391671T3/en
Priority to US12/374,702 priority patent/US7999119B2/en
Priority to SI200730995T priority patent/SI2046740T1/en
Priority to BRPI0714840-2A priority patent/BRPI0714840A2/en
Priority to JP2009520057A priority patent/JP5270542B2/en
Priority to PCT/GB2007/002761 priority patent/WO2008012511A1/en
Priority to NZ574375A priority patent/NZ574375A/en
Priority to NO20090216A priority patent/NO20090216L/en
Priority to ZA200900393A priority patent/ZA200900393B/en
Priority to IL196640A priority patent/IL196640A/en
Priority to HK09109239.3A priority patent/HK1130256A1/en
Priority to US13/180,157 priority patent/US8268878B2/en
Priority to CY20121100744T priority patent/CY1114141T1/en
Ceased legal-status Critical Current

Links

GB0614608A 2006-07-22 2006-07-22 Compounds having CRTH2 antagonist activity Ceased GB0614608D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GB0614608A GB0614608D0 (en) 2006-07-22 2006-07-22 Compounds having CRTH2 antagonist activity
NZ574375A NZ574375A (en) 2006-07-22 2007-07-20 2-(5-fluoro-2-methyI-3-(2-(phenylsulfonyl)benzyl)-1H-indol-1-yl) acetic acid derivatives having CRTH2 antagonist activity
EP12168896A EP2492268A1 (en) 2006-07-22 2007-07-20 Compounds having CRTH2 antagonist activity
US12/374,702 US7999119B2 (en) 2006-07-22 2007-07-20 Compounds having CRTH2 antagonist activity
AU2007279079A AU2007279079A1 (en) 2006-07-22 2007-07-20 Compounds having CRTH2 antagonist activity
RU2009101297/04A RU2458918C2 (en) 2006-07-22 2007-07-20 Compounds showing crth2 antagonist activity
CA002658496A CA2658496A1 (en) 2006-07-22 2007-07-20 2-{5-fluoro-2-methyl-3-[2-(phenylsulfonyl)benzyl]-1h-indol-yl} acetic acid derivatives and esters thereof having crth2 antagonist activity
PL07766323T PL2046740T3 (en) 2006-07-22 2007-07-20 Compounds having crth2 antagonist activity
MX2009000801A MX2009000801A (en) 2006-07-22 2007-07-20 Compounds having crth2 antagonist activity.
DK07766323.5T DK2046740T3 (en) 2006-07-22 2007-07-20 Compounds with CRTH2 antagonistic effect
UAA200900835A UA97957C2 (en) 2006-07-22 2007-07-20 2-{5-fluoro-2-methyl-3-[2-(phenylsulfonyl)benzyl]-1h-indol-1-yl}acetic acid and derivatives thereof, use thereof for the treatment of diseases mediated by pgd2 action at the crth2 receptor
PT07766323T PT2046740E (en) 2006-07-22 2007-07-20 Compounds having crth2 antagonist activity
EP07766323A EP2046740B1 (en) 2006-07-22 2007-07-20 Compounds having crth2 antagonist activity
CN2007800318258A CN101506159B (en) 2006-07-22 2007-07-20 Compounds having CRTH2 antagonist activity
ES07766323T ES2391671T3 (en) 2006-07-22 2007-07-20 Compounds with CRTH2 antagonist activity
KR1020097003615A KR20090042808A (en) 2006-07-22 2007-07-20 Compounds having crth2 antagonist activity
SI200730995T SI2046740T1 (en) 2006-07-22 2007-07-20 Compounds having crth2 antagonist activity
BRPI0714840-2A BRPI0714840A2 (en) 2006-07-22 2007-07-20 compound, process for the preparation and use thereof, pharmaceutical composition, process for the preparation thereof, and, product
JP2009520057A JP5270542B2 (en) 2006-07-22 2007-07-20 Compound having CRTH2 antagonist activity
PCT/GB2007/002761 WO2008012511A1 (en) 2006-07-22 2007-07-20 Compounds having crth2 antagonist activity
NO20090216A NO20090216L (en) 2006-07-22 2009-01-14 Compounds with CRTH2 antagonist activity
ZA200900393A ZA200900393B (en) 2006-07-22 2009-01-16 Compounds having CRTH2 antagonist activity
IL196640A IL196640A (en) 2006-07-22 2009-01-21 2-{5-fluoro-2-methyl-3-[2-(phenylsulfonyl)benzyl]-1h-indol-1-yl}acetic acid and derivatives thereof for treatment of disease mediated by agonists at the crth2 receptor
HK09109239.3A HK1130256A1 (en) 2006-07-22 2009-10-06 Compounds having crth2 antagonist activity
US13/180,157 US8268878B2 (en) 2006-07-22 2011-07-11 Compounds having CRTH2 antagonist activity
CY20121100744T CY1114141T1 (en) 2006-07-22 2012-08-20 UNITS COMPETITING CRTH2 ACTIVITY

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0614608A GB0614608D0 (en) 2006-07-22 2006-07-22 Compounds having CRTH2 antagonist activity

Publications (1)

Publication Number Publication Date
GB0614608D0 true GB0614608D0 (en) 2006-08-30

Family

ID=36998568

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0614608A Ceased GB0614608D0 (en) 2006-07-22 2006-07-22 Compounds having CRTH2 antagonist activity

Country Status (4)

Country Link
CN (1) CN101506159B (en)
GB (1) GB0614608D0 (en)
UA (1) UA97957C2 (en)
ZA (1) ZA200900393B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111458507A (en) * 2020-04-14 2020-07-28 中国人民解放军海军军医大学第三附属医院 Marker for evaluating hepatobiliary carcinoma gemcitabine chemotherapy sensitivity and application thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113684238A (en) * 2021-08-09 2021-11-23 广州医科大学附属第一医院（广州呼吸中心） Use of CXC chemokine receptor 3 as cough drug target
CN114478350B (en) * 2022-01-25 2023-08-11 苏州大学 Preparation method of C3-alkylated indole
CN114609272B (en) * 2022-02-22 2023-08-11 植恩生物技术股份有限公司 Method for detecting mesilate impurity JH-ZZD

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
AU2003231509A1 (en) * 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111458507A (en) * 2020-04-14 2020-07-28 中国人民解放军海军军医大学第三附属医院 Marker for evaluating hepatobiliary carcinoma gemcitabine chemotherapy sensitivity and application thereof
CN111458507B (en) * 2020-04-14 2023-09-12 中国人民解放军海军军医大学第三附属医院 Marker for evaluating sensitivity of intrahepatic bile duct cancer gemcitabine chemotherapy and application thereof

Also Published As

Publication number Publication date
ZA200900393B (en) 2010-03-31
UA97957C2 (en) 2012-04-10
CN101506159B (en) 2012-08-22
CN101506159A (en) 2009-08-12

Similar Documents

Publication Publication Date Title
HK1130256A1 (en) Compounds having crth2 antagonist activity
HK1145175A1 (en) Compounds having crth2 antagonist activity
GB0605743D0 (en) Salts with CRTH2 antagonist activity
GB0722216D0 (en) Use of crth2 antagonist compounds
GB0722203D0 (en) Use of CRTH2 antagonist compounds
IL197714A0 (en) 2-pyridinecarboxamide derivative having gk-activating activity
HU0600809D0 (en) New phenylsulfamoil benzamide derivatives as bradykinin antagonists
IL199430A0 (en) Crth2 antagonists
HRP20130836T1 (en) New benzamide derivatives as bradykinin antagonists
GB0619325D0 (en) New compounds
ZA200900393B (en) Compounds having CRTH2 antagonist activity
ZA200903523B (en) Poly-TLR antagonist
GB0801674D0 (en) Compounds having CRTH2 antagonist activity
GB0625826D0 (en) New compounds
GB0625827D0 (en) New compounds
GB0624176D0 (en) Compounds having CRTH2 antagonist activity
GB0820526D0 (en) Compounds having crth2 antagonist activity
GB0801132D0 (en) Compounds having CRTH2 antagonist activity
GB0801671D0 (en) Compounds having crth2 antagonist activity
GB0801672D0 (en) Compounds having crth2 antagonist activity
GB0801131D0 (en) Compounds having CRTH2 antagonist activity
GB0800874D0 (en) Compounds having CRTH2 antagonist activity
GB0505669D0 (en) Salts with CRTH2 antagonist activity
GB0508681D0 (en) Antagonist
GB0611836D0 (en) New compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)